ICER

Pharma

ICER says AZ's Baxfendy doesn't clear its cost-effectiveness bar

AZ’s newly approved blood pressure drug Baxfendy does not clear the bar for effectiveness relative to its price, says U.S. drug price watchdog ICER.

Kevin Dunleavy Aug 13, 2026 11:37am

FDA

More transparency, evidence needed for accelerated nods: ICER

Apr 17, 2026 11:22am

weight loss scale weigh measure tape obesity overweight

Novo, Lilly obesity meds 'highly cost-effective': ICER report

Sep 9, 2025 10:30am

pharmacoeconomics Leerink

Leerink uses broad model to weigh drugs' cost-effectiveness

Feb 18, 2025 8:56am

drug prices biologics drug costs IRA money cash payment co-pay

ICER calls out drugmakers over 'unsupported' price hikes

Dec 12, 2024 2:24pm

Drug prices

Pfizer's ATTR drug again faces pricing scrutiny

Oct 21, 2024 2:55pm